2015 - Targeted therapy for lung cancer

The main aim of this seminar was to promote the exchange of knowledge and the interaction between basic scientists and clinicians as well as between the different research groups that are currently working on targeted therapy of lung cancer. The participants evaluated advance in lung-cancer targeted therapy so far and defined topics of future research projects aimed to improve the efficacy of targeted drugs as well as their availability to larger subgroups of lung cancer patients.

2015 - Targeted therapy for lung cancer

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Molecular abnormalities and histopathology in lung cancer

Philipp Schnabel (Homburg/Saar, Germany)

Accompanying documents

How to get the tissue for which issues?

Fernando Gamarra (Munich, Germany)

Accompanying documents

Liquid biopsy as an alternative

Rafael Rosell (Badalona, Spain)

Slides

Accompanying documents

Tyrosine Kinase Transmembrane Receptor alterations in NSCLC

Nicolas Girard (Lyon, France)

Accompanying documents

EGFR TKI in the current clinical practice

Jacques Cadranel (Paris, France)

Accompanying documents

Failure of EGFR TKI treatment: mechanisms and current strategies?

Rafael Rosell (Badalona, Spain)

Slides

Accompanying documents

Target other gene point mutations: HER2 and rare EGFR mutations

Federico Cappuzzo (Livorno, Italy)

Accompanying documents

Target gene rearrangements: ALK, ROS and RET

Luis Paz-Ares (Seville, Spain)

Slides

Target amplification/protein surexpression: c met and FGFR

Nicolas Girard (Lyon, France)

Accompanying documents

What have we learn from rebiospy studies?

Anne-Pascale Meert (Brussels, Belgium)

Slides

Accompanying documents

What can we learn from animal models?

Christine Lovly (Nashville, United States of America)

Slides

Accompanying documents

What could we learn from ongoing therapeutic trials?

David Planchard (Roussy-Villejuif, France)

Slides

Accompanying documents

Optimizing the target therapy development

Jacques Cadranel (Paris, France)

Slides

Accompanying documents

Ongoing studies

Thierry Berghmans (Brussels, Belgium)

Slides

Accompanying documents

CDN Connection Issue

2015 - Targeted therapy for lung cancer

2015 - Targeted therapy for lung cancer

#{title}